Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 13/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | JAK1 | P23458 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13455354 | 0.82 | ROCK2 (0.44) | ROCK1ROCK2JAK2MAPK14 | |
| SCHEMBL13421814 | 0.79 | JAK2 (0.39) | ROCK1ROCK2JAK2MAPK14 | |
| SCHEMBL1571757 | 0.75 | ROCK2 (0.59) | ROCK1ROCK2 | |
| SCHEMBL1571758 | 0.75 | ROCK2 (0.59) | ROCK1ROCK2 | |
| SCHEMBL1572375 | 0.75 | ROCK2 (0.59) | ROCK1ROCK2 | |
| SCHEMBL8938640 | 0.75 | ROCK1 (0.76) | ROCK1ROCK2JAK2JAK1 | |
| SCHEMBL17321356 | 0.74 | PARP1 (0.50) | ROCK1ROCK2ALDH1A1MAPK14 | |
| SCHEMBL3315383 | 0.74 | ROCK2 (0.69) | ROCK1ROCK2 | |
| SCHEMBL6326653 | 0.73 | ROCK2 (0.72) | ROCK1ROCK2 | |
| SCHEMBL1571611 | 0.73 | ROCK2 (0.68) | ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119193-A1 | Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same | SAKURAI, YASUHISA (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-19 | — | — | US | disclosed |
| WO-2004080970-A1 | NOVEL BICYCLIC AROMATIC COMPOUNDS, THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119193-A1 | Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same | TYMP, SLC43A1, SLC1A5 | ROCK1 4550/4885ROCK2 4563/4885JAK2 485/4885 |
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | F12, F2, F11 | ROCK1 1604/4885ROCK2 3588/4885JAK2 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.